Another PD-1 Inhibitor, summary info below:
- 42% overall response
- 12% complete response
- $15,000 per month treatment
- $5.1B USD early partnership in 2018
Link: Latecomer GlaxoSmithKline ushers in 7th PD-1/L1 with FDA nod for Jemperli, treading on Keytruda's ground | FiercePharma
With this being the 7th FDA approved PD-1 Inhibitors I think this is putting pressure on Keytruda to maintain market share. If Bisantrene FTO can provide a combination therapy this would be a massive advantage!
We can hopefully have up to 7 companies in a bidding war, although 2 is generally sufficient!
Pillar 1 - FTO (new thread), page-902
-
- There are more pages in this discussion • 2,073 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |